Evidence map›Paper›PMID 27936098›Full record

ArticlePloS one2016

Analysis of HIV Diversity in HIV-Infected Black Men Who Have Sex with Men (HPTN 061).

Iris Chen, Gordon Chau, Jing Wang, William Clarke, Mark A Marzinke, Vanessa Cummings, Autumn Breaud, Oliver Laeyendecker, Sheldon D Fields, Sam Griffith and 10 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 13 institutions in 1 country.

Iris ChenDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Gordon ChauVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Jing WangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
William ClarkeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Mark A MarzinkeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Vanessa CummingsDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Autumn BreaudDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Oliver LaeyendeckerLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, Maryland, United States of America.
Sheldon D FieldsMervyn M. Dymally School of Nursing, Charles R. Drew University of Medicine and Science, Los Angeles, California, United States of America.
Sam GriffithScience Facilitation Department, FHI 360, Durham, North Carolina, United States of America.
Hyman M ScottBridge HIV, San Francisco Department of Public Health, San Francisco, California, United States of America.
Steven ShoptawDepartment of Family Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Carlos Del RioDepartment of Global Health, Emory University Rollins School of Public Health, Atlanta, Georgia, United States of America.
Manya MagnusDepartment of Epidemiology and Biostatistics, Milken Institute School of Public Health at The George Washington University, Washington, District of Columbia, United States of America.
Sharon MannheimerDepartment of Medicine, Harlem Hospital, Columbia University, Mailman School of Public Health, New York, New York, United States of America.
Hong-Van TieuLaboratory of Infectious Disease Prevention, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, United States of America.
Darrell P WheelerSchool of Social Welfare, University at Albany, State University of New York, Albany, New York, United States of America.
Kenneth H MayerThe Fenway Institute, Fenway Health, Boston, Massachusetts, United States of America.
Beryl A KoblinLaboratory of Infectious Disease Prevention, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, United States of America.
Susan H EshlemanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Johns Hopkins University · USJohns Hopkins Medicine · USFred Hutch Cancer Center · USNew York Blood Center · USCharles R. Drew University of Medicine and Science · USColumbia University · USEmory University · USFamily Health International 360 · USFenway Health · USMilken Institute · USSan Francisco Department of Public Health · USUniversity at Albany, State University of New York · USUniversity of California, Los Angeles · US

Funding

LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
Harvard Medical School Vaccine Clinical Trials UnitUM1AI069412 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Lindsey Robert Baden, Daniel R. Kuritzkes · 2012 to 2026
$57.2M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAPHAEL J LANDOVITZ · 1997 to 2026
$53.5M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
TRAINEESHIPS IN AIDS PREVENTION STUDIEST32MH019105 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Carol Suzanne Camlin, Glenn-Milo Santos · 1989 to 2026
$15.3M
Training Program in Cellular and Molecular MedicineT32GM008752 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAO, RAJINI · 2000 to 2019
$11.7M
Laboratory and Statistical Development of Cross-Sectional HIV Incidence AssaysR01AI095068 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ESHLEMAN, SUSAN H · 2011 to 2021
$6.6M
Minority Populations Prevention Researcher TrainingR25HD045810 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NEILANDS, TORSTEN BRIAN · 2003 to 2018
$4.3M
Sexual Networks, Drugs, and HIV Risk among Men Who Have Sex With MenK01DA031035 · NIDA · NEW YORK BLOOD CENTER · PI TIEU, HONG VAN NHU · 2011 to 2015
$862k
NIAID NIH HHS R01 AI095068NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI069412NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069470NICHD NIH HHS R25 HD045810NIDA NIH HHS K01 DA031035NIGMS NIH HHS T32 GM008752NIMH NIH HHS P30 MH058107NIMH NIH HHS T32 MH019105
6 · The paper itself

Abstract

backgroundHIV populations often diversify in response to selective pressures, such as the immune response and antiretroviral drug use. We analyzed HIV diversity in Black men who have sex with men who were enrolled in the HIV Prevention Trials Network 061 study.

methodsA high resolution melting (HRM) diversity assay was used to measure diversity in six regions of the HIV genome: two in gag, one in pol, and three in env. HIV diversity was analyzed for 146 men who were HIV infected at study enrollment, including three with acute infection and 13 with recent infection (identified using a multi-assay algorithm), and for 21 men who seroconverted during the study. HIV diversification was analyzed in a paired analysis for 62 HIV-infected men using plasma samples from the enrollment and 12-month (end of study) visits.

resultsMen with acute or recent infection at enrollment and seroconverters had lower median HRM scores (lower HIV diversity) than men with non-recent infection in all six regions analyzed. In univariate analyses, younger age, higher CD4 cell count, and HIV drug resistance were associated with lower median HRM scores in multiple regions; ARV drug detection was marginally associated with lower diversity in the pol region. In multivariate analysis, acute or recent infection (all six regions) and HIV drug resistance (both gag regions) were associated with lower median HRM scores. Diversification in the pol region over 12 months was greater for men with acute or recent infection, higher CD4 cell count, and lower HIV viral load at study enrollment.

conclusionsHIV diversity was significantly associated with duration of HIV infection, and lower gag diversity was observed in men who had HIV drug resistance. HIV pol diversification was more pronounced in men with acute or recent infection, higher CD4 cell count, and lower HIV viral load.

Indexed as

Genetic VariationAdultAnti-HIV AgentsBlack or African AmericanDrug Resistance, ViralHIVHIV InfectionsHomosexuality, MaleHumansMaleMiddle AgedUnited StatesYoung AdultAnti-HIV Agents

Identifiers

PMID27936098
PMCPMC5147928
OpenAlexW2560485652

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.